Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Health Ministry nod to...

    Health Ministry nod to MeRes100- India made bioresorbable cardiac Stent

    Written by savita thakur thakur Published On 2017-02-24T11:31:24+05:30  |  Updated On 14 Aug 2021 11:49 AM IST

    New Delhi: Meril Life Science, a Gujarat based global medical device company has received the green signal from the Health Ministry for the country's first locally made bioresorbable cardiac scaffold, or naturally dissolving stent.


    Micron-thick BVS 'MeRes100' is made of material that degrades and is absorbed by the body over three years.


    In a meeting held on Tuesday, Meril Life sciences presented their case regarding the bioresorbable cardiac scaffold stent to subject expert committee (SEC), where the committee gave approval for their bioresorbable cardiac scaffold stent.


    Sanjeev Bhatt, vice president (corporate strategy) at Meril Life Sciences, in an email response to ET said, "We have presented our case to the Subject Expert Committee and are awaiting feedback."


    After Abbott India, Meril Life Science would be the second company with a BVS in the country which has made a bioresorbable cardiac stent.Last year in July, the USFDA approved the Abbott's first fully absorbable stent to treat coronary artery disease. The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS).


    Read also: USFDA gives nod to Abott's ABSORB stent


    Speaking with ET, Sanjeev Bhatt, vice president (corporate strategy) at Meril Life Sciences said Meril had first applied for approval for MeRes100 in India in 2013.


    Explaining the Benefits of bioresorbable cardiac scaffold, Bhatt said before introducing their case in from of Health Ministry, the Company conducted studies in 108 patients in India and 40 patients in Brazil, European countries and South East Asian countries. It has already received approvals to market the product in Columbia, Ecuador, Indonesia and the Philippines over the last month and is currently awaiting regulatory approvals from the European Union, he added.


    Although the price of bioresorbable cardiac scaffold is higher than ordinary stents but some doctors find BVS a good choice for young patients between 25-45 years because it dissolves and could give them a relatively better quality of life than metallic drug eluting stents.


    Columbia Asia senior consultant Sanjat Chiwane told ET, "If you believe in the science, a scaffold that dissolves would reduce the need for patients to be on several medications for a long time. It would be an ideal therapy for anybody because you don't have a device inside your body forever."


    Talking about the efficiency of drug eluting stents, Chiwane said drug eluting stents are also efficient as BVS stent. There is no one study which had proved that BVS are more efficient than drug eluting stents. Elaborating the importance of bioresorbable cardiac stents he further said, "They're not superior to second or third generation stents, but they're not inferior either."


    bioresorbable cardiac scaffoldbioresorbable cardiac stentDissolvable StentHealth MinistryMeRes100Meril Life ScienceStent
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok